Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on September 30, 2019, detailing significant debt financing activities. The company issued a substantial amount of senior notes denominated in Euros, totaling approximately €4.4 billion, with varying maturities and coupon rates ranging from 0.125% to 1.875%. These Euro-denominated notes were issued through a public offering registered on Form S-3. Additionally, the company announced plans to issue approximately $900 million in USD-denominated senior notes with a 2.600% coupon due in 2029, scheduled for October 8, 2019. The primary purpose of these new debt issuances is to refinance existing debt. Specifically, the proceeds will be used to repay commercial paper used for recent redemptions and to fund the redemption of approximately $4.5 billion in outstanding senior notes. This includes the full redemption of certain notes issued by the company and its subsidiary, Life Technologies Corporation, which were slated for redemption on October 15, 2019. This strategic debt management aims to optimize the company's capital structure and potentially lower borrowing costs.
Key Highlights
- 1Thermo Fisher Scientific issued approximately €4.4 billion in senior notes across five tranches with maturities from 2025 to 2049 and low coupon rates.
- 2The company plans an additional $900 million issuance of senior notes due 2029 with a 2.600% coupon.
- 3Proceeds from these offerings are earmarked for refinancing existing debt, including repaying commercial paper and redeeming approximately $4.5 billion of outstanding senior notes.
- 4The Euro Offering occurred on September 30, 2019, under a Form S-3 registration statement.
- 5The USD Offering is scheduled for October 8, 2019.
- 6The newly issued notes are general unsecured obligations and rank equally with existing unsecured and unsubordinated indebtedness.
- 7The company also announced the redemption of several tranches of existing notes on October 15, 2019, aggregating over $3.2 billion in principal.